Skip to main content
SpringerLink
Log in

Drug Treatment of Patients with Schizophrenia

  • Chapter
Contemporary Psychiatry

  • 25 Accesses

Abstract

Ever since antipsychotic drug treatment was introduced into clinical psychiatry almost half a century ago,establishing a breakthrough in the management of schizophrenic disorders, this new therapeutic area has been characterized by a continuing attempt to optimize the results of treatment efforts for these patients. A plethora of medications, called neuroleptics in classical terminology, a term increasingly replaced by the indication-driven word antipsychotics, has been synthesized and tested to this end. Molecules of different chemical structures, ranging from tricyclic phenothiazines to thioxanthenes, butyrophenones, dibenzazepines, substituted benzamides and benzisoxazole derivatives are now used in the treatment of schizophrenia. The development of clozapine was clearly a quantum leap in these efforts.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Adler LA, Edson R, Lavori P, Peselow E, Duncan E, Rosenthal M, Rotrosen J (1998) Long-term treatment effects of vitamin Efor tardive dyskinesia. Biol Psychiatry 43: 868–872

    Article  PubMed  CAS  Google Scholar 

  • Aitchison K, Kerwin R (1997) Cost-effectiveness of clozapine. Br J Psychiatry 171: 125–130

    Article  PubMed  CAS  Google Scholar 

  • Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156(11): 1686–1696

    PubMed  CAS  Google Scholar 

  • Altamura CA, Colacurcio F, Mauri MC, Moro AR, DeNovellis F (1989) Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels. Prog Neuropsychopharmacol Biol Psychiatry 14: 25–35

    Article  Google Scholar 

  • Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA (1993) Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 329: 162–167

    Article  PubMed  CAS  Google Scholar 

  • American Psychiatric Association (1992) Tardive dyskinesia: a task force report of the American Psychiatric Association. American Psychiatric Press, Washington, DC

    Google Scholar 

  • American Psychiatric Association (1997) Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 54[Suppl]

    Google Scholar 

  • Arato M, O’Connor R, Meltzer H, Bradbury J (1997) Ziprasidone: efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia. Eur Neuropsychopharmacol 7[Suppl 2]: 214

    Article  Google Scholar 

  • Arvanitis LA, Miller BG, Seroquel Trial 13 Study Group (1997) Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42: 233–246

    Article  PubMed  CAS  Google Scholar 

  • Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance ofneuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45: 79–91

    Article  PubMed  CAS  Google Scholar 

  • Barnas C, Stuppäck C, Miller C, Haring C, Sperner-Unterweger B, Fleischhacker WW (1992) Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms: a double blind trial vs. haloperidol. Int Clin Psychopharmacol 7: 23–27

    Article  PubMed  CAS  Google Scholar 

  • Bäuml J, Kissling W, Buttner P, Pitschell-Walz G, Mayer C, Boerner R, Engel R, Peuker I, Welschehold M (1993) Informationszentrierte Patienten- und Angehörigengruppen zur Complianceverbesserung bei schizophrenen Psychosen. Verhaltenstherapie 3[Suppl 1]: 1–96

    Article  Google Scholar 

  • Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S (1996) Olanzapine versus placebo and haloperidol. Neuropsychopharmacology 14: 111–123

    Article  PubMed  CAS  Google Scholar 

  • Bissette G, Nemeroff CB (1995) The neurobiology of neurotensin. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven, New York, pp 573–583

    Google Scholar 

  • Blackwell B (1973) Drug therapy. N Engl J Med 2: 249–252

    Article  Google Scholar 

  • Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P, on Behalf of the Risperidone Study Group (1998) Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 155: 499–504

    PubMed  CAS  Google Scholar 

  • Borison RL, Arvanitis LA, Miller BG, Seroquel Study Group (1996) ICI 204.636. An atypical antipsychotic: efficacy and safety in a multicenter, placebo controlled trial in patients with schizophrenia. J Clin Psychopharmacol 16: 158–169

    Article  PubMed  CAS  Google Scholar 

  • Buchanan A (1992) A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 22: 787–797

    Article  PubMed  CAS  Google Scholar 

  • Bunney BG, Bunney WE, Carlsson A (1995) Schizophrenia and glutamate. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven, New York, pp 1205–1214

    Google Scholar 

  • Byerly MJ, DeVane CL (1996) Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 16: 177–187

    Article  PubMed  CAS  Google Scholar 

  • Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14: 87–96

    Article  PubMed  CAS  Google Scholar 

  • Caligiuri MP, Lohr JB, Jeste DV (1993) Parkinsonism inneuroleptic-naive schizophrenic patients. Am J Psychiatry 150: 1343–1348

    PubMed  CAS  Google Scholar 

  • Carpenter WT (1996) The treatment of negative symptoms: pharmacological and methodological issues. Br J Psychiatry 168[Suppl 29]: 17–22

    Google Scholar 

  • Carpenter WT, Hanlon TE, Heinrichs DW, Summerfeit AT, Kirkpatrick B, Levine J, Buchanan RW (1990) Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 147: 1138–1148

    PubMed  Google Scholar 

  • Casey DE (1996) Extrapyramidal syndromes: epidemiology, pathophysiology and the diagnostic dilemma. CNS Drugs 5[Suppl 1]: 1–12

    Article  Google Scholar 

  • Chatterjee A, Chakos M, Koreen AR, Geisler S, Sheitman B, Woerner M, Kane JM, Alvir JMJ, Lieberman MA (1995) Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenicpatients. Am J Psychiatry 152: 1724 –1729

    PubMed  CAS  Google Scholar 

  • Claghorn J, Honigfeld G, Abuzzahab FS, Wang R, Steinbook R, Tuason V, Klerman GL (1987) The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7: 377–384

    Article  PubMed  CAS  Google Scholar 

  • Collins PJ, Larkin EP, Shubsachs APW (1991) Lithium carbonate in chronic schizophrenia — a brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients. Acta Psychiatr Scand 84: 150–154

    Article  PubMed  CAS  Google Scholar 

  • Cooper SJ, Butler A, Tweed J, Welch C, Raniwalla J (2000) Zotepine in the prevention of recurrence: a double-blind, placebo controlled study in chronic schizophrenics. Psychopharmacology (accepted for publication)

    Google Scholar 

  • Coryell W, Miller DD, Perry PJ (1998) Haloperidol plasma levels and dose optimization. Am J Psychiatry 155: 48–53

    PubMed  CAS  Google Scholar 

  • Crow TJ, McMillan JF, Johnson AL, Johnstone EC (1986) The Northwick Park study of first episodes of schizophrenia. II. A randomized controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 148: 120–127

    Article  PubMed  CAS  Google Scholar 

  • Csernansky JG, Newcomer JG (1995) Maintenance drug treatment for schizophrenia. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven, New York, pp 1267–1275

    Google Scholar 

  • Daniel DG, Wozniak P, Mack RJ, McCarthy BG, Sertindole StudyGroup (1998) Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol Bull 34: 61–69

    PubMed  CAS  Google Scholar 

  • Danion JM, Neunreuther C, Krieger-Finance F, Imbs JL, Singer L (1987) Compliance with long-term lithium treatment in major affective disorders. Pharmacopsychiatry 20: 230–231

    Article  PubMed  CAS  Google Scholar 

  • Davis JM, Kane JM, Marder S, Brauzer B, Gierl B, Schooler NR, Casey DE, Hassan M (1993) Dose response of prophylactic antipsychotics. J Clin Psychiatry 54[Suppl 3]: 24–30

    PubMed  Google Scholar 

  • Davis JM, Matalon L, Watanabe MD, Blake LM (1994) Depot antipsychotic drugs; place in therapy. Drugs 47: 741–773

    Article  PubMed  CAS  Google Scholar 

  • Davis R, Markham A (1997) Ziprasidone. CNS Drugs 8: 153–159

    Article  PubMed  CAS  Google Scholar 

  • Decina P, Mukherjee S, Bocola V, Saraceni F, Hadjichristos C, Scapicchio P (1994) Adjunctive trazodone in the treatment of negative symptoms of schizophrenia. Hosp Comm Psychiatry 45: 1220–1223

    CAS  Google Scholar 

  • Deutch AY, Duman RS (1996) The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization. Neuroscience 70: 377–389

    Article  PubMed  CAS  Google Scholar 

  • Dieterle DM, Müller-Spahn F, Ackenheil M (1991) Efficacy and tolerance of zotepine in a double-blind comparison with perazine in schizophrenics. Fortschr Neurol Psychiatr 59[Suppl 4]: 18–22

    Article  PubMed  Google Scholar 

  • Drake RE, Osher FC, Wallach MA (1989) Alcohol use and abuse in schizophrenia. J Nerv Ment Dis 177: 408–414

    Article  PubMed  CAS  Google Scholar 

  • Duinkerke SJ, Botter PA, Jansen AAI, Van Dongen PAM, Van Haaften AJ, Boom AJ, Van Laarhoven JHM, Busard HLSM (1993) Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia: a placebo-controlled double-blind trial. Br J Psychiatry 163: 451–455

    Article  PubMed  CAS  Google Scholar 

  • Dunn CJ, Fitton A (1996) Sertindole. CNS Drugs 5: 224–230

    Article  CAS  Google Scholar 

  • Eckman TA, Liberman RP, Phipps CC, Blair KE (1990) Teaching medication management skills to schizophrenic patients. J Clin Psychopharmacol 10: 33–38

    Article  PubMed  CAS  Google Scholar 

  • Farde L, Nyberg S (1998) Dosing determination for novel antipsychotics — a PET-based approach. Int J Psychiatr Clin Pract 2[Suppl 1]: 39–42

    Google Scholar 

  • Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) PET analysis of central D, and D2 dopamine receptor occupancy in patients treated with classic neuroleptics andclozapine — relationship to extrapyramidal side effects. Arch Gen Psychiatry 49: 538–544

    Article  PubMed  CAS  Google Scholar 

  • Fayen M, Goldman MB, Moulthrop MA, Luchins DJ (1988) Differential memory function with dopaminergic versus anticholinergic treatment of drug induced extrapyramidal symptoms. Am J Psychiatry 145: 483–486

    PubMed  CAS  Google Scholar 

  • Fenton WS, Blyler CR, Heinssen RK (1997) Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Res 23: 637–651

    CAS  Google Scholar 

  • Fischer-Cornelssen KA, Ferner VJ (1976) An example of European multicenter trials: multispectral analysis of clozapine. Psychopharmacol Bull 2: 34–39

    Google Scholar 

  • Fitton A, Heel R (1990) Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40: 722–747

    Article  PubMed  CAS  Google Scholar 

  • Fleischhacker WW (1999) Clozapine: a comparison with other novel antipsychotics. J Clin Psychiatry 60[Suppl 12]: 30–34

    PubMed  CAS  Google Scholar 

  • Fleischhacker W, Hummer M (1997) Drug treatment of schizophrenia in the 1990s: achievements and future possibilities in optimising outcomes. Drugs 53: 915–929

    Article  PubMed  CAS  Google Scholar 

  • Fleischhacker WW, Barnas C, Günther V, Meise U, Stuppäck CH, Unterweger B (1987) Mood-altering effects of biperiden inhealthy volunteers. J Affect Disord 12: 153–157

    Article  PubMed  CAS  Google Scholar 

  • Fleischhacker WW, Barnas C, Stuppäck CH, Unterweger B, Miller CH, Hinterhuber H (1989) Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial. Psychopharmacol Bull 25: 97–100

    PubMed  CAS  Google Scholar 

  • Fleischhacker WW, Roth SD, Kane JM (1990) The pharmacologictreatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 10: 12–21

    Article  PubMed  CAS  Google Scholar 

  • Fleischhacker WW, Hummer M, Kurz M, Kurzthaler I, Lieberman J, Pollack S, Safferman A, Kane J (1994a) Clozapine dose in the US and Europe: implications for therapeutic and adverse effects. J Clin Psychiatry 55[Suppl B]: 78–81

    PubMed  Google Scholar 

  • Fleischhacker WW, Meise U, Günther V, Kurz M (1994b) Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand [Suppl 382]: 11–15

    Google Scholar 

  • Fulton B, Goa KL (1995) ICI-204,636. An initial appraisal of itspharmacological properties and clinical potential in the treatment of schizophrenia. CNS Drugs 4: 68–78

    Article  Google Scholar 

  • Gaebel W, Falkai P (1998) Praxisleitlinien in Psychiatrie und Psychotherapie, vol 1: Behandlungsleitlinie Schizophrenie. Steinkopff, Darmstadt

    Book  Google Scholar 

  • Gardos G, Cole JO (1995) The treatment of tardive dyskinesia. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven, New York, 1503–1511

    Google Scholar 

  • Gardos G, Casey DE, Cole JO, Perenyi A, Kocsis E, Arato M,Samson J, Conley C (1994) Ten-year outcome of tardive dyskinesia. Am J Psychiatry 151: 836–841

    PubMed  CAS  Google Scholar 

  • Gerlach I, Koppelhus P, Helweg E, Monrad A (1974) Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 50: 410–424

    Article  PubMed  CAS  Google Scholar 

  • Gilbert PL, Harris MJ, McAdams LA, Jeste DV (1995) Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 52: 173–188

    Article  PubMed  CAS  Google Scholar 

  • Glazer WM, Johnstone BM (1997) Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry 58[Suppl 10]: 50–54

    PubMed  Google Scholar 

  • Goff DC, Brotman AW, Waites M, McCormick S (1990) Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 47: 492–494

    Google Scholar 

  • Goff DC, Kamal KM, Sarid-Segal O, Hubbard JW, Amico E (1995) A placebo-controlled trial of fluoxetine added to neuroleptics in patients with schizophrenia. Psychopharmacology 117: 417–423

    Article  PubMed  CAS  Google Scholar 

  • Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko GN (1998) An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 18: 296–304

    Article  PubMed  CAS  Google Scholar 

  • Goldberg TE, Gold JM (1995) Neurocognitive deficits in schizophrenia. In: Hirsch SR, Weinberger DR (eds) Schizophrenia. Blackwell, Oxford, pp 146–162

    Google Scholar 

  • Green M, Marshall B, Wirshing W, Ames D, Marder S, McGurk S,Kern RS, Mintz J (1997) Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 154: 799–804

    PubMed  CAS  Google Scholar 

  • Growe GA, Crayton JA, Klass DB (1979) Lithium in chronic schizophrenia. Am J Psychiatry 136: 454–455

    PubMed  CAS  Google Scholar 

  • Hale A, Van der Burght M, Wehnert A, Friberg HH (1996) A European dose-range study comparing the efficacy, tolerability and safety of four doses of sertindole and one dose ofhaloperidol in schizophrenic patients. Poster presented at the20th CINP Congress, Melbourne, 23–27 June

    Google Scholar 

  • Hamilton SH, Revicki DA, Genduso LA, Beasley CM Jr. (1998) Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 18: 41–49

    Article  PubMed  CAS  Google Scholar 

  • Haring C, Fleischhacker WW, Schett P, Humpel C, Barnas C, Saria A (1990) Influence of patient-related variables onclozapine plasma levels. Am J Psychiatry 147: 1471–1475

    PubMed  CAS  Google Scholar 

  • Haring C, Neudorfer C, Schwitzer J, Hummer M, Saria A, Hinterhuber H, Fleischhacker WW (1994) EEG alterations inpatients treated with clozapine in relation to plasma levels. Psychopharmacology 114: 97–100

    Article  PubMed  CAS  Google Scholar 

  • Herz MI, Glazer WM, Mostert MA, Sheard MA, Szymanski HV (1991) Intermittent vs. maintenance medication in schizophrenia: two-year results. Arch Gen Psychiatry 48: 333–339

    Article  PubMed  CAS  Google Scholar 

  • Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Müller H (1994) Elevated serum levels of clozapine afteraddition of fluvoxamine. Clin Psychopharmacol 14: 279–281

    Article  CAS  Google Scholar 

  • Hirsch S, Link CG, Goldstein JM, Arvanitis LA (1996) ICI 204,636. A new atypical antipsychotic drug. Br J Psychiatry 168[Suppl 29]: 45–56

    Google Scholar 

  • Hoge SK, Appelbaum PS, Lawlor T, Beck JC, Litman F, Greer A,Gutheil TG, Kaglun E (1990) A prospective, multicenter study of patients’ refusal of antipsychotic medication. Arch Gen Psychiatry 47: 949–956

    Article  PubMed  CAS  Google Scholar 

  • Hummer M, Fleischhacker WW (1999) Ways of improvingcompliance. In: Lader M, Naber D (eds) Difficult clinical problems in psychiatry. Martin Dunitz, London, pp 229–238

    Google Scholar 

  • Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW (1999) Sexual disturbances during clozapine and haloperidol treatment. Am J Psychiatry 156: 631–633

    PubMed  CAS  Google Scholar 

  • Janicak PG, Javaid JI, Sharma RP, Leach A, Dowd S, Davis JM (1997) A two-phase, double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders. Acta Psychiatr Scand 95: 343–350

    Article  PubMed  CAS  Google Scholar 

  • Johnson DAW (1979) Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia. Br J Psychiatry 135: 524–530

    Article  PubMed  CAS  Google Scholar 

  • Jolley AG, Hirsch SR, McRink A, Manchanda R (1989) Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. Br Med J 298: 985–990

    Article  CAS  Google Scholar 

  • Kane JM, Lieberman JA (1987) Maintenance pharmacotherapy in schizophrenia. In: Meltzer HY (ed) Psychopharmacology — the third generation of progress. Raven, New York, pp 1103–1109

    Google Scholar 

  • Kane JM, Honigfeld G, Singer J, Meltzer H Y (1988a) Clozapine forthe treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789–796

    Article  PubMed  CAS  Google Scholar 

  • Kane JM, Woerner M, Lieberman J (1988b) Tardive dyskinesia: prevalence, incidence and risk factors. J Clin Psychopharmacol 8: 52S–56S

    Article  PubMed  CAS  Google Scholar 

  • Kane JM, Aguglia E, Altamura AC et al (1998) Guidelines fordepot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 8(1): 55–66

    Article  PubMed  CAS  Google Scholar 

  • Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR, Ziprasidone Study Group (1998) Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebocontrolled trial. Psychopharmacology 140: 173–184

    Article  PubMed  CAS  Google Scholar 

  • Kemp R, Kirov G, Everitt B, Hayward P, David A (1998) Randomised controlled trial of compliance therapy. Br J Psychiatry 172: 413–419

    Article  PubMed  CAS  Google Scholar 

  • Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen AR,Weiden PJ (1993) Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 29: 309–314

    PubMed  CAS  Google Scholar 

  • Kissling W (1991) Duration of neuroleptic maintenance treatment. In: Kissling W (ed) Guidelines for neuroleptic relapse prevention in schizophrenia. Springer, Berlin Heidelberg New York, pp 94–112

    Chapter  Google Scholar 

  • Kissling W, Kane JM, Barnes TRE, Dencker SJ, Fleischhacker WW, Goldstein JM, Johnson DAW, Marder SR, Müller-Spahn F, Tegeler J et al (1991) Guidelines for neuroleptic relapse prevention in schizophrenia: towards a consensus view. In: Kissling W (ed) Guidelines for neuroleptic relapse prevention in schizophrenia. Springer, Berlin Heidelberg New York, pp 155–163

    Chapter  Google Scholar 

  • Klieser E, Lehmann E, Tegeler J (1991) Double-blind comparison of 3 × 75 mg zotepine and 3 × 4 mg haloperidol in acute schizophrenics. Fortschr Neurol Psychiatr 59[Suppl 1]: 14–17

    Article  PubMed  Google Scholar 

  • Kolakowska T, Williams AO, Ardern M, Reveley MA, Jambor K, Gelder MG, Mandelbrote BM (1985) Schizophrenia with good and poor outcome. I. Early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry 146: 229–246

    Article  PubMed  CAS  Google Scholar 

  • Kraepelin E (1919) Dementia praecox and paraphrenia. Livingstone, Edinburgh

    Google Scholar 

  • Krueger RB, Sackheim HA (1995) Electroconvulsive therapy and schizophrenia. In: Hirsch SR, Weinberger DR (eds) Schizophrenia. Blackwell Science, Oxford, pp 503–545

    Google Scholar 

  • Kurz M, Hummer M, Oberbauer H, Fleischhacker WW (1995a) Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology 118: 52–56

    Article  PubMed  CAS  Google Scholar 

  • Kurz M, Hummer M, Kurzthaler I, Oberbauer H, Fleischhacker WW (1995b) Efficacy of medium-dose clozapine for treatment resistant schizophrenia. Am J Psychiatry 152:1690–1691

    PubMed  CAS  Google Scholar 

  • Lehmann AF, Steinwachs DM, Co-investigators of the PORT project (1998) At issue: translating research into practice: the schizophrenia patient outcomes research team (PORT) treatment recommendations. Schizophr Bull 24: 1–10

    Article  Google Scholar 

  • Lemmens P, Brecher M, Van Baelen B (1999) A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 99(3): 160–170

    Article  PubMed  CAS  Google Scholar 

  • Levinson DF, Simpson GM, Singh H, Yadalam K, Jain A, Stephanos MJ, Silver P (1990) Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry 47: 761–768

    Article  PubMed  CAS  Google Scholar 

  • Levinson DF, Singh H, Simpson GM (1992) Timing of acute clinical response to fluphenazine. Br J Psychiatry 160: 365–371

    Article  PubMed  CAS  Google Scholar 

  • Levinson DF, Simpson GM, Lo ES, Cooper TB, Singh H, Yadalam K, Stephanos M J (1995) Fluphenazine plasma levels, dosage, efficacy, and side effects. Am J Psychiatry 152: 765–771

    PubMed  CAS  Google Scholar 

  • Ley P, Spelman MS (1965) Communication in an outpatient setting. Br J Soc Clin Psychol 4: 114–116

    Article  PubMed  CAS  Google Scholar 

  • Liddle PF, Barnes TRE, Curson DA, Patel M (1993) Depression and the experience of psychological deficits in schizophrenia. Acta Psychiatr Scand 88: 243–247

    Article  PubMed  CAS  Google Scholar 

  • Loebel A, Lieberman J, Alvir J, Geisler J, Koreen A, Chakos M (1995) Time to treatment response in successive episodes of early onset schizophrenia. Schizophr Res 15: 158

    Article  Google Scholar 

  • Loo H, Poirier-Littre M-F, Theron M, Rein W, Fleurot O (1997) Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170: 18–22

    Article  PubMed  CAS  Google Scholar 

  • Maj M, Sartorius N (eds) (1999) Schizophrenia. Wiley, New York

    Google Scholar 

  • Mandoki MW (1995) Risperidone treatment of children and adolescents: increased risk of extrapyramidal side effects? J Child Adolesc Psychopharmacol 5: 49–67

    Article  Google Scholar 

  • Marder SR (1998) Facilitating compliance with antipsychotic medication. J Clin Psychiatry 59[Suppl 3]: 21–25

    PubMed  Google Scholar 

  • Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151: 825–835

    PubMed  CAS  Google Scholar 

  • McEvoy JP, Hogarty GE, Steingard S (1991) Optimal dose of neuroleptics in acute schizophrenia. Arch Gen Psychiatry 48: 739–745

    Article  PubMed  CAS  Google Scholar 

  • Meise U, Günther V, Gritsch S (1992) Die Bedeutung der Arzt-Patienten-Beziehung für die Patientencompliance. Wien Klin Wochenschr 104: 267–271

    PubMed  CAS  Google Scholar 

  • Meltzer HY (1989) Duration of a clozapine trial in neurolepticresistant schizophrenia. Arch Gen Psychiatry 46: 672

    Article  PubMed  CAS  Google Scholar 

  • Meltzer HY, Okayli G (1995) The reduction of suicidality during clozapine treatment in neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 152: 183–190

    PubMed  CAS  Google Scholar 

  • Meltzer HY, Burnett S, Bastani B, Ramirez LF (1990) Effects of 6 months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Comm Psychiatry 41: 892–897

    CAS  Google Scholar 

  • Middelboe T (1995) Predictors of treatment compliance in longterm mentally ill. Eur Neuropsychopharmacol 5(3): 318

    Article  Google Scholar 

  • Miller CH, Fleischhacker WW (2000) Managing antipsychotic - induced acute and chronic akathisia. Drug Safety 22(1): 73–81

    Article  PubMed  CAS  Google Scholar 

  • Miller DD, Fleming F, Holman TL, Perry PJ (1994) Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 55[Suppl 13]: 117–121

    PubMed  Google Scholar 

  • Möller HJ (1995) The negative component in schizophrenia. Acta Psychiatr Scand 91[Suppl 388]: 11–14

    Article  Google Scholar 

  • >Möller HJ, van Zerssen D (1995) Course and outcome of schizophrenia. In: Hirsch SR, Weinberger DR (eds) Schizophrenia. Blackwell Science, Oxford, pp 106–127

    Google Scholar 

  • Mortimer A (1997) Cognitive function in schizophrenia — do neuroleptics make a difference? Pharmacol Biochem Behav 56: 789–795

    Article  PubMed  CAS  Google Scholar 

  • Nordström A, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995) Dl, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152: 1444–1449

    PubMed  Google Scholar 

  • Nyberg S, Farde L, Halldin C (1997) A PET study of 5-HT2 and D2 clozapine receptor occupancy induced by olanzapine inhealthy subjects. Neuropsychopharmacology 16: 1–7

    Article  PubMed  CAS  Google Scholar 

  • Pan PC, Tantam D (1989) Clinical characteristics, health beliefsand compliance with maintenance treatment: a comparison between regular and irregular attenders at a depot clinic. Acta Psychiatr Scand 79: 564–570

    Article  PubMed  CAS  Google Scholar 

  • Perlick D, Mattis S, Stasny P, Teresi J (1992) Neuropsychologicaldiscriminators of long-term inpatient or outpatient status in chronic schizophrenia. J Neuropsychiatr Clin Neurosci 4: 428–434

    CAS  Google Scholar 

  • Petit M, Raniwalla J, Tweed J, Leutenegger E, Dollfus S, Kelly F (1996) A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel group double-blind trial. Psychopharmacol Bull 32: 81–87

    PubMed  CAS  Google Scholar 

  • Peuskens J (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166: 712–726

    Article  PubMed  CAS  Google Scholar 

  • Pfeiffer W, Kockott G, Fischl B, Schleuning G (1991) Unerwünschte Wirkungen psychopharmakologischer Langzeittherapie auf die sexuellen Funktionen. Psychiatr Prax 18: 92–98

    PubMed  CAS  Google Scholar 

  • Pietzcker A, Gaebel W, Kopeke W, Linden M, Müller P, Müller-Spahn F, Tegeler J (1993) Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia — 2-year results of a German multicenter study. J Psychiatr Res 27: 321–339

    Article  Google Scholar 

  • Pilowsky LS, O’Connell P, Davies N, Busatto GF, Costa DC, Murray PJ, Kerwin RW (1997) In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole — a 123 IIBZM single photon emission tomography (SPET) study. Psychopharmacology 130: 152–158

    Article  PubMed  CAS  Google Scholar 

  • Potkin SG, Bera R, Gulasekaram B, Jin Y, Costa J, Gerber B,Richmond G, Ploszaj D, Carreon D, Cooper T, Sitanggan K (1994) Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 55[Suppl B]: 133–136

    PubMed  Google Scholar 

  • Prakash A, Lamb HM (1998) Zotepine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 9: 154–175

    Google Scholar 

  • Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD (2000) Neuropsychological change in early phase schizophrenia during 12 month treatment witholanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 57(3): 249–258

    Article  PubMed  CAS  Google Scholar 

  • Remington G, Bezchlibnyk-Butier K (1996) Management ofacute antipsychotic-induced extrapyramidal syndromes. CNS Drugs 5[Suppl 1]: 21–35

    Article  Google Scholar 

  • Rifkin A, Doddi S, Karagi B (1991) Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 48: 166–170

    Article  PubMed  CAS  Google Scholar 

  • Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D (1997) A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 337: 809–815

    Article  PubMed  CAS  Google Scholar 

  • Roth BL, Meltzer HY (1995) The role of serotonin in schizophrenia. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven, New York, pp 1215–1227

    Google Scholar 

  • Rowley H, Kilpatrick L, Needham P, Heat D (1998) Elevation of extracellular cortical noradrenaline may contribute to the antidepressant activity of zotepine: an in vivo microdialysis study in freely moving rats. Neuropharmacology 37: 937–944

    Article  PubMed  CAS  Google Scholar 

  • Roy A (1990) Relationship between depression and suicidal behaviour in schizophrenia. In: DeLisi LE (ed) Depression in schizophrenia. American Psychiatric Press, Washington, DC

    Google Scholar 

  • Sailer FC, Salama AJ (1993) Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 112: 285–292

    Article  Google Scholar 

  • Schall U, Catts S, Chaturvedi S, Liebert B, Redenbach J, Karayanidis F, Ward P (1998) The effect of clozapine therapy on frontal lobe dysfunction in schizophrenia: neuropsychology and event-related potential measures. Int J Neuropsychopharmacol 1: 19–29

    Article  PubMed  CAS  Google Scholar 

  • Schmutz J, Hunziker F, Stille G, Lauener H (1967) Constitution chimique et action pharmacologique d’un nouveau groupe de neuroleptiques tricycliques. Bull Chim Therapeut 424

    Google Scholar 

  • Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, Hargreaves WA, Kane JM, Ninan PT, Frances A et al (1997) Relapse and rehospitalization during maintenance treatment of schizophrenia — the effects of dose reduction and family treatment. Arch Gen Psychiatry 54: 453–463

    Article  PubMed  CAS  Google Scholar 

  • Schou M (1997) The combat of non-compliance during prophylactic lithium treatment. Acta Psychiatr Scand 95: 361–363

    Article  PubMed  CAS  Google Scholar 

  • Schultz SK, Miller DD, Arndt S, Ziebell S, Gupta S, Andreasen NC (1995) Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation. Biol Psychiatry 38: 713–719

    Article  PubMed  CAS  Google Scholar 

  • Schulz SC, Kahn EM, Baker RW, Conley RR (1990) Lithium and carbamazepine augmentation in treatment refractory schizophrenia. In: Angrist B, Schulz SC (eds) The neurolepticnonresponsive patient: characterization and treatment. American Psychiatric Association, Washington DC, pp 109–136

    Google Scholar 

  • Schwartz D, Wang W, Zeitz L, Goss ME (1962) Medication errorsmade by elderly, chronically ill patients. Am J Public Health 52: 2018–2029

    Article  CAS  Google Scholar 

  • Shalev A, Hermesh H, Rothberg J, Munitz H (1993) Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatr Scand 87: 86–91

    Article  PubMed  CAS  Google Scholar 

  • Sharma T, Mockler D (1998) The cognitive efficacy of atypical antipsychotics in schizophrenia. J Clin Psychopharmacol 18[Suppl 1]: 12S–19S

    Article  PubMed  CAS  Google Scholar 

  • Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, Modai L, Khaikin M, Weitman A (1997) Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled study. Br J Psychiatry 171: 569–573

    Article  PubMed  CAS  Google Scholar 

  • Silver H, Kushnir M, Kaplan A (1996) Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study. Biol Psychiatry 40: 671–674

    Article  PubMed  CAS  Google Scholar 

  • Silverstone T, Smith G, Goodall E (1988) Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 153: 214–217

    Article  PubMed  CAS  Google Scholar 

  • Siris SG (1995) Depression and schizophrenia. In: Hirsch SR, Weinberger DR (eds) Schizophrenia. Blackwell Science, Oxford, pp 128–145

    Google Scholar 

  • Skarsfeldt T (1995) Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 281: 289–294

    Article  PubMed  CAS  Google Scholar 

  • Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG, Seroquel Study Group (1997) Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison withplacebo. Arch Gen Psychiatry 54: 549–557

    Article  PubMed  CAS  Google Scholar 

  • Smith JM (1980) Abuse of antiparkinsonian drugs — a review of the literature. J Clin Psychiatry 41: 351–354

    PubMed  CAS  Google Scholar 

  • Steingard S, Allen M, Schooler NR (1994) A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse. J Clin Psychiatry 55: 470–472

    PubMed  CAS  Google Scholar 

  • Sternlicht HC, Wells SR (1995) Risperidone in childhood schizophrenia. J Am Acad Child Adolesc Psychiatry 34: 5

    Article  Google Scholar 

  • Stille G, Hippius H (1971) Kritische Stellungnahme zum Begriff der Neuroleptika. Pharmakopsychiatr Neuropharmakol 4: 182–191

    Article  CAS  Google Scholar 

  • Swett J, Noones J (1989) Factors associated with premature termination from outpatient treatment. Hosp Comm Psychiatr 40: 947–951

    Google Scholar 

  • Tandon R, Mann NA, Eisner WH, Coppard N (1990) Effect of anticholinergic medication on positive and negative symptoms in medication free schizophrenic patients. Psychiatry Res 31: 235–241

    Article  PubMed  CAS  Google Scholar 

  • Tandon R, Harrigan E, Zorn SH (1997) Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 4: 159–177

    Google Scholar 

  • Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JH (1997a) Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 154: 1248–1254

    PubMed  CAS  Google Scholar 

  • Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thierne ME (1997b) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154: 457–465

    PubMed  CAS  Google Scholar 

  • Tollefson GD, Sanger TM, Beasley CM (1997c) Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154: 466–474

    PubMed  CAS  Google Scholar 

  • Tollefson GD, Sanger TM, Thierne ME (1998) Depressive signsand symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 55: 250–258

    Article  PubMed  CAS  Google Scholar 

  • Tran PV, Dellva MA, Tollefson GD, Beasley CM, Potvin JH, Kiesler GM (1997) Extrapyramidal symptoms and tolerabilityof olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 58: 205–211

    Article  PubMed  CAS  Google Scholar 

  • Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley CM (1998) Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 172: 499–505

    Article  PubMed  CAS  Google Scholar 

  • Travis MJ, Busatto GF, Pilowsky LS, Mulligan R, Acton PD, Gacinovic S, Mertens J, Terrière D, Costa DC, Ell PJ et al (1998) 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine: a SPECT study using the novel 5-HT2A ligand 123 I-5-I-R-91150. Br J Psychiatry 173: 236–241

    Article  PubMed  CAS  Google Scholar 

  • VanderZwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB (1996) Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 153: 1579–1584

    PubMed  CAS  Google Scholar 

  • Van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS (1998) Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao extrapyramidal syndromes study III. Am J Psychiatry 155: 565–567

    PubMed  Google Scholar 

  • Van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree T, Sertindole Study Group (1996) A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 124: 168–175

    Article  PubMed  Google Scholar 

  • Van Putten T (1974) Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 31: 67–72

    Article  PubMed  Google Scholar 

  • Van Putten T, Marder SR, Mintz J, Poland RE (1992) Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 149: 500–505

    PubMed  Google Scholar 

  • Volavka J, Cooper T, Czobor P, Bitter I, Meisner M, Laska E, Gastanaga P, Krakowski M, Chou SCY, Crowner M et al (1992) Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 49: 354–361

    Article  PubMed  CAS  Google Scholar 

  • Weiss F, Danzl C, Hummer M, Kemmler G, Lindner C, Reinstadler K, Fleischhacker WW (1998) Weight gain induced by olanzapine. Schizophr Res 29 (special issue 1–2): 179

    Article  Google Scholar 

  • Whitworth AB, Fleischhacker WW (1995) Adverse effects ofantipsychotic drugs. Int Clin Psychopharmacol 9[Suppl 5]: 21–27

    Article  PubMed  Google Scholar 

  • Wilson WH (1993) Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial.Psychopharmacology 111: 359–366

    Article  PubMed  CAS  Google Scholar 

  • Wirshing WC, Marder SR, Van Putten T, Ames D (1995) Acute treatment of schizophrenia. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven, New York, pp 1259–1266

    Google Scholar 

  • Wolkowitz OM, Rapoport MH, Pickar D (1990) Benzodiazepine augmentation of neuroleptics. In: Angrist B, Schulz SC (eds) The neuroleptic nonresponsive patient: characterization and treatment. American Psychiatric Association, Washington DC, pp 87–108

    Google Scholar 

  • World Health Organization (1990) Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. Br J Psychiatry 156: 412–414

    Article  Google Scholar 

  • Wyatt RJ (1992) Neuroleptics and the natural course of schizophrenia. Schizophr Bull 17: 325–351

    Article  Google Scholar 

  • Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak TJ, Sebree TB, Wallin BA, Kashkin KB, Sertindole Study Group (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154: 782–791

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. W. W. Fleischhacker
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Zentralinstitut für Seelische Gesundheit, P.O. Box 12 21 20, 68072, Mannheim, Germany

    Fritz Henn

  2. Belle-Idée, Bâtiment Salève, Hôpitaux Universitaires de Genève, 2, chemin du Petit-Bel-Air, 1225, Chêne-Bourg/Genève, Switzerland

    Norman Sartorius

  3. Psychiatrische Klinik, Freie Universität Berlin, Eschenallee 3, 14050, Berlin, Germany

    Hanfried Helmchen

  4. Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Germany

    Hans Lauter

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Fleischhacker, W.W. (2001). Drug Treatment of Patients with Schizophrenia. In: Henn, F., Sartorius, N., Helmchen, H., Lauter, H. (eds) Contemporary Psychiatry. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59519-6_95

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59519-6_95

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64007-0

  • Online ISBN: 978-3-642-59519-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation